Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Andrew E, Schade"'
Autor:
Aaron M. Gruver, Haiyan Lu, Xiaoxian Zhao, Angie D. Fulford, Michael D. Soper, Darryl Ballard, Jeffrey C. Hanson, Andrew E. Schade, Eric D. Hsi, Klaus Gottlieb, Kelly M. Credille
Publikováno v:
Diagnostic Pathology, Vol 18, Iss 1, Pp 1-12 (2023)
Abstract Background Histologic evaluation of the mucosal changes associated with celiac disease is important for establishing an accurate diagnosis and monitoring the impact of investigational therapies. While the Marsh-Oberhuber classification has b
Externí odkaz:
https://doaj.org/article/77800cfdc1234688b422c739cee2d36c
Autor:
David S. Hong, Ramon V. Tiu, Michael S. Gordon, Ilaria Conti, Karim A. Benhadji, Sheng-Bin Peng, James R. Henry, Michael D. Kaufman, Daniel L. Flynn, KrisAnne Crowe, Andrew E. Schade, Danni Yu, Melinda D. Willard, Amanda Sykes, Ling Gao, Wei Zhang, Michael J. Millward, Jordi Rodon Ahnert, Geoffrey I. Shapiro, Keith T. Flaherty, Antoine Hollebecque, Ryan J. Sullivan
Supplementary Figure S2 shows two cases of patients treated at the RP2D. IHC at Clarient for p-ERK, p27 and Ki-67 were assessed for PD effect using monoclonal rabbit phospho-p44/42 MAPK (ERK1/2), 20G11 Clone; monoclonal mouse anti-Ki67, MIB-1 clone;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bffa344fba1fa66a45a3628b0bc99d4
https://doi.org/10.1158/1535-7163.22521469
https://doi.org/10.1158/1535-7163.22521469
Autor:
Geoffrey I. Shapiro, Patrick Y. Wen, Keith T. Flaherty, Edward M. Chan, Damien M. Cronier, Martin Frenzel, Lily Q. Li, Palaniappan Kulanthaivel, Ricardo Martinez, Tuan S. Nguyen, Angie D. Fulford, Andrew E. Schade, Richard P. Beckmann, Aejaz Nasir, John F. Hilton, Drew W. Rasco, Muralidhar Beeram, Kyriakos P. Papadopoulos, Leena Gandhi, Jonathan W. Goldman, Anthony W. Tolcher, Sara M. Tolaney, Lee S. Rosen, Amita Patnaik
Supplementary Table 1. Summary of 33 Patients Treated with Abemaciclib in Dose Escalation. Supplementary Table 2. Baseline patient and disease characteristics. Supplementary Table 3. Possibly related treatment-emergent adverse events (>10% all grades
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36991b4fd4f6f7c7f083e22b6e2c0a5d
https://doi.org/10.1158/2159-8290.22531521
https://doi.org/10.1158/2159-8290.22531521
Publikováno v:
Cancer Cell International, Vol 17, Iss 1, Pp 1-12 (2017)
Abstract Background Clinically relevant predictive biomarkers to tailor anti-angiogenic therapies to breast cancer (BRC) patient subpopulations are an unmet need. Methods We analyzed tumor vascular density and VEGFR2 protein expression in various sub
Externí odkaz:
https://doaj.org/article/8143f028811a47df9aa322e4180d0112
Autor:
Jack Knorr, Russell Perry, Peter Chen, Corey Hebert, Richard E. Higgs, Mark D. Williams, Joseph Boscia, Bharat Mocherla, Masoud Azizad, Princy Kumar, Robert L. Gottlieb, Paul Klekotka, Dipak R. Patel, Ajay Nirula, Imad Shawa, Andra L. Blomkalns, Andrew C. Adams, Gregory D. Huhn, Kenneth L. Custer, Lei Shen, Timothy R. Holzer, Jason Morris, Philip J. Ebert, Andrew E. Schade, Jacob Van Naarden, Blaze investigators, Gerard J. Oakley, Jose Cardona, Janelle Sabo, Matan C. Dabora, Daniel Skovronsky, Chad Crystal, Barry Heller, Awawu Igbinadolor, Michael Dougan
Publikováno v:
Clinical Infectious Diseases. 75:e440-e449
Background Based on interim analyses and modeling data, lower doses of bamlanivimab and etesevimab together (700/1400 mg) were investigated to determine optimal dose and expand availability of treatment. Methods This Phase 3 portion of the BLAZE-1 tr
Autor:
Gregory D. Huhn, Dipak R. Patel, Bharat Mocherla, Daniel Skovronsky, Kenneth L. Custer, Paul Klekotka, Imad Shawa, Andrew E. Schade, Janelle Sabo, Nicole L. Kallewaard, Michael Durante, Andrew C. Adams, Timothy R. Holzer, Ajay Nirula, Joseph Boscia, Masoud Azizad, Jose Cardona, Princy Kumar, Chad Crystal, Lei Shen, Peter Chen, Russell Perry, Corey Hebert, Richard E. Higgs, Robert L. Gottlieb, Matan C. Dabora, Philip J. Ebert, Jacob Van Naarden, Gerard J. Oakley, Jason Morris, Michael Dougan, Awawu Igbinadolor, Barry Heller
Publikováno v:
The New England Journal of Medicine
Background Patients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment provides immediate, passive i
Autor:
Michael J. Pontecorvo, Ming Lu, Samantha C. Burnham, Andrew E. Schade, Jeffrey L. Dage, Sergey Shcherbinin, Emily C. Collins, John R. Sims, Mark A. Mintun
Publikováno v:
JAMA neurology.
ImportancePlasma biomarkers of Alzheimer disease may be useful as minimally invasive pharmacodynamic measures of treatment outcomes.ObjectiveTo analyze the association of donanemab treatment with plasma biomarkers associated with Alzheimer disease.De
Autor:
Timothy R. Holzer, Sameera R. Wijayawardana, Gerard J. Oakley, Narasimha Marella, Holly Kay Cannon, Jessica A. Roseberry Baker, Anthony N. Sireci, Juraj Bodo, Joel D. Cook, Tyler J Marquart, Andrew E. Schade, Eric D. Hsi, Leslie O'Neill Reising
Publikováno v:
Archives of Pathology & Laboratory Medicine. 146:351-359
Context.— RET gene fusions are oncogenic drivers in nonsmall cell lung cancer and nonmedullary thyroid cancer. Selpercatinib (RETEVMO), a targeted inhibitor of RET, was approved by the US Food and Drug Administration for the treatment of RET fusion
Autor:
Bradley L. Ackermann, Ryan D. Morrison, Salisha Hill, Matthew D. Westfall, Brent D. Butts, Michael D. Soper, Jeff A. Fill, Andrew E. Schade, Daniel C. Liebler, Aaron M. Gruver
Publikováno v:
Laboratory Investigation. 103:100052
Autor:
Ajay Nirula, Jason Morris, Valentina Stosor, Gerard J. Oakley, Robert L. Gottlieb, Gregory D. Huhn, Jacob Van Naarden, Bharat Mocherla, Peter Chen, Joseph Boscia, Janelle Sabo, Daniel Skovronsky, Dipak R. Patel, Kenneth L. Custer, Michael Durante, Lei Shen, Paul Klekotka, Imad Shawa, Andrew E. Schade, Andrew C. Adams, Jose Cardona, Barry Heller
Publikováno v:
New England Journal of Medicine
The New England Journal of Medicine
The New England Journal of Medicine
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and life-threatening. Virus-neutralizing monoclonal antibodies are predicted to reduce